JPWO2020018852A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020018852A5 JPWO2020018852A5 JP2021526401A JP2021526401A JPWO2020018852A5 JP WO2020018852 A5 JPWO2020018852 A5 JP WO2020018852A5 JP 2021526401 A JP2021526401 A JP 2021526401A JP 2021526401 A JP2021526401 A JP 2021526401A JP WO2020018852 A5 JPWO2020018852 A5 JP WO2020018852A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 185
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 2
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 102000048776 human CD274 Human genes 0.000 claims 1
- 102000044459 human CD47 Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024103530A JP2024133536A (ja) | 2018-07-18 | 2024-06-27 | 新規な抗体ならびにそれを調製および使用するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862700174P | 2018-07-18 | 2018-07-18 | |
| US62/700,174 | 2018-07-18 | ||
| US201962792798P | 2019-01-15 | 2019-01-15 | |
| US62/792,798 | 2019-01-15 | ||
| PCT/US2019/042493 WO2020018852A2 (en) | 2018-07-18 | 2019-07-18 | Novel antibodies and methods for making and using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103530A Division JP2024133536A (ja) | 2018-07-18 | 2024-06-27 | 新規な抗体ならびにそれを調製および使用するための方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021530251A JP2021530251A (ja) | 2021-11-11 |
| JPWO2020018852A5 true JPWO2020018852A5 (https=) | 2023-03-10 |
| JP2021530251A5 JP2021530251A5 (https=) | 2023-03-10 |
| JP7513605B2 JP7513605B2 (ja) | 2024-07-09 |
Family
ID=69165232
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526401A Active JP7513605B2 (ja) | 2018-07-18 | 2019-07-18 | 新規な抗体ならびにそれを調製および使用するための方法 |
| JP2024103530A Pending JP2024133536A (ja) | 2018-07-18 | 2024-06-27 | 新規な抗体ならびにそれを調製および使用するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103530A Pending JP2024133536A (ja) | 2018-07-18 | 2024-06-27 | 新規な抗体ならびにそれを調製および使用するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11505618B2 (https=) |
| EP (1) | EP3824096A4 (https=) |
| JP (2) | JP7513605B2 (https=) |
| CN (1) | CN112513093B (https=) |
| WO (1) | WO2020018852A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11505618B2 (en) * | 2018-07-18 | 2022-11-22 | Askgene Pharma Inc. | Antibodies and methods for making and using the same |
| CA3128502A1 (en) | 2019-02-01 | 2020-08-06 | Novarock Biotherapeutics, Ltd. | Anti-claudin 18 antibodies and methods of use thereof |
| WO2021160154A1 (zh) * | 2020-02-10 | 2021-08-19 | 上海诗健生物科技有限公司 | Cldn18.2抗体及其用途 |
| IL298184A (en) * | 2020-05-15 | 2023-01-01 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Antibody drug conjugate, preparation method therefor and use thereof |
| WO2022012559A1 (zh) * | 2020-07-13 | 2022-01-20 | 上海君实生物医药科技股份有限公司 | 抗cldn-18.2抗体及其用途 |
| CN113929780A (zh) * | 2020-07-13 | 2022-01-14 | 北京凯因科技股份有限公司 | 一种结合密蛋白的用于治疗癌症的人源化抗体 |
| CN111704669B (zh) * | 2020-07-13 | 2022-05-13 | 北京凯因科技股份有限公司 | 一种用于治疗晚期胃癌的抗cldn18全人源化抗体 |
| US20240034784A1 (en) * | 2020-09-30 | 2024-02-01 | Nanjing GenScript Biotech Co., Ltd. | Antibodies targeting human claudin 18.2 and uses thereof |
| CN114504642B (zh) * | 2020-11-17 | 2026-03-27 | 江苏奥赛康生物医药有限公司 | 一种含抗cldn18.2抗体的液体药物组合物 |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| CA3199830A1 (en) | 2020-12-23 | 2022-06-30 | Lukas BAMMERT | Tumor-specific claudin 18.2 antibody-drug conjugates |
| CN114805571B (zh) * | 2021-01-28 | 2023-08-25 | 广西鹭港生物医药科技有限公司 | 抗cldn18.2抗体及其应用 |
| EP4299593A4 (en) * | 2021-04-02 | 2025-12-10 | Oricell Therapeutics Co Ltd | CLDN18.2 ANTIGEN-BINDING PROTEIN AND ITS USE |
| CN115611983A (zh) * | 2021-07-14 | 2023-01-17 | 三优生物医药(上海)有限公司 | Cldn18.2结合分子及其用途 |
| WO2024137619A1 (en) | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| KR20250129814A (ko) | 2023-01-18 | 2025-08-29 | 타이리간드 바이오사이언스 (상하이) 리미티드 | 항체-약물 접합체 및 이의 용도 |
| WO2024173387A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| EP4716702A2 (en) * | 2023-05-22 | 2026-04-01 | SystImmune, Inc. | Anti-claudin18.2 antibody and method of making and using thereof |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025082356A1 (zh) * | 2023-10-16 | 2025-04-24 | 江苏奥赛康生物医药有限公司 | Cldn18_2抗体与化学治疗药物的组合及其应用 |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2026050213A1 (en) | 2024-08-27 | 2026-03-05 | Usbolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014127785A1 (en) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| WO2018026742A1 (en) * | 2016-08-01 | 2018-02-08 | Askgene Pharma Inc. | Novel antibody-albumin-drug conjugates (aadc) and methods for using them |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| WO2019173832A2 (en) * | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| US11505618B2 (en) * | 2018-07-18 | 2022-11-22 | Askgene Pharma Inc. | Antibodies and methods for making and using the same |
-
2019
- 2019-07-18 US US16/516,223 patent/US11505618B2/en active Active
- 2019-07-18 EP EP19838910.8A patent/EP3824096A4/en active Pending
- 2019-07-18 WO PCT/US2019/042493 patent/WO2020018852A2/en not_active Ceased
- 2019-07-18 CN CN201980029283.3A patent/CN112513093B/zh active Active
- 2019-07-18 JP JP2021526401A patent/JP7513605B2/ja active Active
-
2022
- 2022-11-21 US US17/991,775 patent/US12312413B2/en active Active
-
2024
- 2024-06-27 JP JP2024103530A patent/JP2024133536A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020018852A5 (https=) | ||
| US10913796B2 (en) | Antibodies targeting Fc receptor-like 5 and methods of use | |
| RU2766094C2 (ru) | Антитела, нацеленные на антиген созревания в-клеток, и способы их применения | |
| JP2024156657A5 (https=) | ||
| JP2010502183A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| JP7649744B2 (ja) | Ｂｔｎ３ａ結合タンパク質及びその使用 | |
| JP2020508655A5 (https=) | ||
| JP2021522162A5 (https=) | ||
| JP2021515798A5 (https=) | ||
| HRP20170374T1 (hr) | Biološki proizvodi | |
| JP2015163068A5 (https=) | ||
| HRP20020693B1 (hr) | HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß | |
| JP2018522888A5 (https=) | ||
| JP2005528914A5 (https=) | ||
| JP7830445B2 (ja) | インターロイキン１アルファに特異的な真のヒト抗体 | |
| JP2019505477A5 (https=) | ||
| KR20230082626A (ko) | 인터루킨 1 알파에 특이적인 실제 인간 항체 | |
| US20210261689A1 (en) | Anti-bcma car antibodies, conjugates, and methods of use | |
| JP2016529213A5 (https=) | ||
| KR20230082629A (ko) | 인터루킨 1 알파에 특이적인 실제 인간 항체 | |
| KR20230082628A (ko) | 인터루킨 1 알파에 특이적인 실제 인간 항체 | |
| JPWO2019204564A5 (https=) | ||
| FI3681911T3 (fi) | Ihmisen trombiinireseptori PAR4:ään sitoutuvia proteiineja | |
| CN109293774A (zh) | 特异性结合cd19的全人源化抗体及应用 |